HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.
Elisa Agostinetto,Elisa Agostinetto,Mattia Rediti,Danai Fimereli,Véronique Debien,Martine Piccart,Philippe Aftimos,Christos Sotiriou,Evandro de Azambuja +8 more
Reads0
Chats0
TLDR
In this article, the distribution of PAM50 intrinsic subtypes within HER2-low BC subtypes according to hormonal receptor status (positive (HR+) and negative (HR−), and the impact of HER2low status on survival outcomes (progression free interval (PFI), disease-free interval (DFI), and overall survival (OS)).Abstract:
Background: We aimed to determine the distribution of intrinsic subtypes within HER2-low breast cancer (BC), and to describe the prognostic impact of HER2-low status on survival outcomes. Methods: This is a retrospective, observational study of primary BC extracted from The Cancer Genome Atlas dataset. We described the distribution of PAM50 intrinsic subtypes within HER2-low BC subtype according to hormonal receptor status (positive (HR+) and negative (HR−)). Secondly, we assessed the impact of HER2-low on survival outcomes (progression-free interval (PFI), disease-free interval (DFI), and overall survival (OS)). Results: We analyzed 804 primary BCs, including 410 (51%) HER2-low BCs (336 HR+ and 74 HR−). The proportion of HER2-enriched tumors was higher in the HER2-low/HR− group compared to HER2-low/HR+ (13.7% versus 1.2%, respectively). HER2-enriched tumors were more frequent in HER2-low/HR− and HER2-low/HR+ subtypes, compared to HER2-negative/HR− and HER2-negative/HR+ subtypes, respectively (13.7% versus 1.6% and 1.2% versus 0.5%, respectively). We observed no significant differences in PFI, DFI, and OS between HER2-low subtypes and each non-HER2-low subtype paired by HR status. Conclusions: Our characterization of PAM50 intrinsic subtypes within HER2-low breast cancer may explain the different clinical behaviors and responses to treatment, and ultimately support further investigation of new treatment strategies in the HER2-low category. Moreover, it highlights the importance of considering HR status in the HER2-low category.read more
Citations
More filters
Journal ArticleDOI
Evolution of low HER2 expression between early and advanced-stage breast cancer.
Paolo Tarantino,Sara Gandini,Eleonora Nicolò,P. Trillo,Federica Giugliano,P. Zagami,Grazia Vivanet,Federica Bellerba,Dario Trapani,Antonio Marra,Angela Esposito,Carmen Criscitiello,Giuseppe Viale,Giuseppe Curigliano +13 more
TL;DR: In this paper , the evolution of low human epidermal growth factor receptor 2 (HER2) expression during the course of disease is still poorly characterised, and controversial data exist on its prognostic implications.
Journal ArticleDOI
Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society
Hye Sung Won,Juneyoung Ahn,Yonghyun Kim,Jin Sung Kim,Jeong Yoon Song,Hong Kyu Kim,Jeeyeon Lee,Heung Kyu Park,Yong-Seok Kim +8 more
TL;DR: Kim et al. as discussed by the authors explored the differences in clinicopathological characteristics and survival outcomes between HER2-low and HER2IHC 0 breast cancer, and showed that the impact of low HER2 expression on breast cancer-specific survival was significant only in triple-negative breast cancer (HRs, 0.68; 95% CI, 049-0.93; P = 0.019).
Journal ArticleDOI
Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society
Hye Sung Won,Juneyoung Ahn,Yonghyun Kim,Jin Sung Kim,Jeong Yoon Song,Hong Kyu Kim,Jeeyeon Lee,Heung Kyu Park,Yong-Seok Kim +8 more
TL;DR: Kim et al. as mentioned in this paper explored the differences in clinicopathological characteristics and survival outcomes between HER2-low and HER2IHC 0 breast cancer, and showed that the impact of low HER2 expression on breast cancer-specific survival was significant only in triple-negative breast cancer (HRs, 0.68; 95% CI, 049-0.93; P = 0.019).
Journal ArticleDOI
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Paolo Tarantino,Qingchun Jin,Nabihah Tayob,Rinath Jeselsohn,Stuart J. Schnitt,Julie Vincuilla,Toni Trent Parker,Svitlana Tyekucheva,Tianyu Li,Nan Lin,Melissa E. Hughes,Anna Weiss,Tari A. King,Elizabeth A. Mittendorf,Giuseppe Curigliano,Sara M. Tolaney +15 more
TL;DR: The results of this cohort study did not support the interpretation of ERBB2-low breast cancer as a distinct biologic subtype and suggested that, given the worse prognosis of ER-low tumors, they may be associated with confounding of prognostic analyses of ER BB2- low expression.
Journal ArticleDOI
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
Ryan Ying Cong Tan,Whee Sze Ong,Kyung Eun Lee,Abner Herbert Lim,Seri Park,Yeon Hee Park,Ching-Hung Lin,Yen-Shen Lu,Makiko Ono,Takayuki Ueno,Yoichi Naito,Tatsuya Onishi,Geok Hoon Lim,Su-Ming Tan,Han-Byoel Lee,Han Suk Ryu,Wonshik Han,Veronique Kiak Mien Tan,Fuh Yong Wong,Seock-Ah Im,Puay Hoon Tan,Jason Yongsheng Chan,Yoon Sim Yap +22 more
TL;DR: In this paper , the authors evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-metastatic breast cancer (BC) from 6 centers within the Asian Breast Cancer Cooperative Group (ABCCG) (n = 28,280) were analyzed.
References
More filters
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt,Robert S. Fulton,Michael D. McLellan,Heather Schmidt,Joelle Kalicki-Veizer,Joshua F. McMichael,Lucinda Fulton,David J. Dooling,Li Ding,Elaine R. Mardis,Richard K. Wilson,Adrian Ally,Miruna Balasundaram,Yaron S.N. Butterfield,Rebecca Carlsen,Candace Carter,Andy Chu,Eric Chuah,Hye Jung E. Chun,Robin J.N. Coope,Noreen Dhalla,Ranabir Guin,Carrie Hirst,Martin Hirst,Robert A. Holt,Darlene Lee,Haiyan I. Li,Michael Mayo,Richard A. Moore,Andrew J. Mungall,Erin Pleasance,A. Gordon Robertson,Jacqueline E. Schein,Arash Shafiei,Payal Sipahimalani,Jared R. Slobodan,Dominik Stoll,Angela Tam,Nina Thiessen,Richard Varhol,Natasja Wye,Thomas Zeng,Yongjun Zhao,Inanc Birol,Steven J.M. Jones,Marco A. Marra,Andrew D. Cherniack,Gordon Saksena,Gordon Saksena,Robert C. Onofrio,Nam H. Pho,Scott L. Carter,Steven E. Schumacher,Steven E. Schumacher,Barbara Tabak,Barbara Tabak,Bryan Hernandez,Jeff Gentry,Huy Nguyen,Andrew Crenshaw,Kristin G. Ardlie,Rameen Beroukhim,Rameen Beroukhim,Wendy Winckler,Gad Getz,Gad Getz,Stacey Gabriel,Matthew Meyerson,Matthew Meyerson,Lynda Chin,Lynda Chin,Raju Kucherlapati,Katherine A. Hoadley,J. Todd Auman,Cheng Fan,Yidi J. Turman,Yan Shi,Ling Li,Michael D. Topal,Xiaping He,Hann Hsiang Chao,Aleix Prat,Grace O. Silva,Michael D. Iglesia,Wei Zhao,Jerry Usary,Jonathan S. Berg,Michael C. Adams,Jessica K. Booker,Junyuan Wu,Anisha Gulabani,Tom Bodenheimer,Alan P. Hoyle,Janae V. Simons,Matthew G. Soloway,Lisle E. Mose,Stuart R. Jefferys,Saianand Balu,Joel S. Parker,D. Neil Hayes,Charles M. Perou,Simeen Malik,Swapna Mahurkar,Hui Shen,Daniel J. Weisenberger,Timothy J. Triche,Phillip H. Lai,Moiz S. Bootwalla,Dennis T. Maglinte,Benjamin P. Berman,David Van Den Berg,Stephen B. Baylin,Peter W. Laird,Chad J. Creighton,Lawrence A. Donehower,Michael S. Noble,Doug Voet,Nils Gehlenborg,Daniel Di Cara,Juinhua Zhang,Hailei Zhang,Chang-Jiun Wu,Spring Yingchun Liu,Michael S. Lawrence,Lihua Zou,Andrey Sivachenko,Pei Lin,Petar Stojanov,Rui Jing,Juok Cho,Raktim Sinha,Richard W. Park,Marc Danie Nazaire,James A. Robinson,Helga Thorvaldsdottir,Jill P. Mesirov,Peter J. Park,Sheila Reynolds,Richard Kreisberg,Brady Bernard,Ryan Bressler,Timo Erkkilä,Jake Lin,Vesteinn Thorsson,Wei Zhang,Ilya Shmulevich,Giovanni Ciriello,Nils Weinhold,Nikolaus Schultz,Jianjiong Gao,Ethan Cerami,Benjamin Gross,Anders Jacobsen,Rileen Sinha,B. Arman Aksoy,Yevgeniy Antipin,Boris Reva,Ronglai Shen,Barry S. Taylor,Marc Ladanyi,Chris Sander,Pavana Anur,Paul T. Spellman,Yiling Lu,Wenbin Liu,Roel R.G. Verhaak,Gordon B. Mills,Gordon B. Mills,Rehan Akbani,Nianxiang Zhang,Bradley M. Broom,Tod D. Casasent,Chris Wakefield,Anna K. Unruh,Keith A. Baggerly,Kevin R. Coombes,John N. Weinstein,David Haussler,Christopher C. Benz,Joshua M. Stuart,Stephen C. Benz,Jingchun Zhu,Christopher Szeto,Gary K. Scott,Christina Yau,Evan O. Paull,Daniel E. Carlin,Christopher K. Wong,Artem Sokolov,Janita Thusberg,Sean D. Mooney,Sam Ng,Theodore C. Goldstein,Kyle Ellrott,Mia Grifford,Christopher Wilks,Singer Ma,Brian Craft,Chunhua Yan,Ying Hu,Daoud Meerzaman,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Jay Bowen,Nilsa C. Ramirez,Nilsa C. Ramirez,Aaron D. Black,Robert E. Pyatt,Robert E. Pyatt,Peter White,Peter White,Erik Zmuda,Jessica Frick,Tara M. Lichtenberg,Robin Brookens,Myra M. George,Mark Gerken,Hollie A. Harper,Kristen M. Leraas,Lisa Wise,Teresa R. Tabler,Cynthia McAllister,Thomas Barr,Melissa Hart-Kothari,Katie Tarvin,Charles Saller,George E. Sandusky,Colleen Mitchell,Mary Iacocca,Jennifer Brown,Brenda Rabeno,Christine Czerwinski,Nicholas J. Petrelli,Oleg Dolzhansky,Mikhail Abramov,Olga Voronina,Olga Potapova,Jeffrey R. Marks,Wiktoria Maria Suchorska,Dawid Murawa,Witold Kycler,Matthew Ibbs,Konstanty Korski,Arkadiusz Spychała,Pawel Murawa,Jacek J. Brzeziński,Hanna Perz,Radoslaw Łaźniak,M. Teresiak,Honorata Tatka,Ewa Leporowska,Marta Bogusz-Czerniewicz,Julian Malicki,Andrzej Mackiewicz,Maciej Wiznerowicz,Xuan Van Le,Bernard Kohl,Nguyen Viet Tien,Richard Thorp,Nguyen Van Bang,Howard H. Sussman,Bui Duc Phu,Richard A. Hajek,Nguyen Phi Hung,Huynh Quyet Thang,Khurram Z. Khan,Robert Penny,David Mallery,Erin Curley,Candace Shelton,Peggy Yena,James N. Ingle,Fergus J. Couch,Wilma L. Lingle,Tari A. King,Ana M. Gonzalez-Angulo,Ana M. Gonzalez-Angulo,Mary D. Dyer,Shuying Liu,Xiaolong Meng,Modesto Patangan,Frederic Waldman,Frederic Waldman,Hubert Stoppler,W. Kimryn Rathmell,Leigh B. Thorne,Mei Huang,Lori Boice,Ashley Hill,Carl Morrison,Carmelo Gaudioso,Wiam Bshara,Kelly Daily,Sophie C. Egea,Mark D. Pegram,Carmen Gomez-Fernandez,Rajiv Dhir,Rohit Bhargava,Adam Brufsky,Craig D. Shriver,Jeffrey A. Hooke,Jamie Leigh Campbell,Richard J. Mural,Hai Hu,Stella Somiari,Caroline Larson,Brenda Deyarmin,Leonid Kvecher,Albert J. Kovatich,Matthew J. Ellis,Thomas Stricker,Kevin P. White,Olufunmilayo I. Olopade,Chunqing Luo,Yaqin Chen,Ron Bose,Li-Wei Chang,Andrew H. Beck,Todd Pihl,Mark A. Jensen,Robert Sfeir,Ari B. Kahn,Anna Chu,Prachi Kothiyal,Zhining Wang,Eric E. Snyder,Joan Pontius,Brenda Ayala,Mark Backus,Jessica Walton,Julien Baboud,Dominique L. Berton,Matthew C. Nicholls,Deepak Srinivasan,Rohini Raman,Stanley Girshik,Peter A. Kigonya,Shelley Alonso,Rashmi N. Sanbhadti,Sean P. Barletta,David Pot,Margi Sheth,John A. Demchok,Kenna R. Mills Shaw,Liming Yang,Greg Eley,Martin L. Ferguson,Roy Tarnuzzer,Jiashan Zhang,Laura A.L. Dillon,Kenneth H. Buetow,Peter Fielding,Bradley A. Ozenberger,Mark S. Guyer,Heidi J. Sofia,Jacqueline D. Palchik +355 more
TL;DR: The ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity.
Journal ArticleDOI
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker,Michael Mullins,Maggie C.U. Cheang,Samuel Leung,David Voduc,Tammi L. Vickery,Sherri R. Davies,Christiane Fauron,Xiaping He,Zhiyuan Hu,John Quackenbush,Inge J. Stijleman,Juan P. Palazzo,James Stephen Marron,Andrew B. Nobel,Elaine R. Mardis,Torsten O. Nielsen,Matthew J. Ellis,Charles M. Perou,Philip S. Bernard +19 more
TL;DR: D diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer.
Journal ArticleDOI
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C. Wolff,M. Elizabeth H. Hammond,David G. Hicks,Mitch Dowsett,Lisa M. McShane,Kimberly H. Allison,D. C. Allred,John M. S. Bartlett,Michael Bilous,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Pamela B. Mangu,Soonmyung Paik,Edith A. Perez,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Daniel F. Hayes +19 more
TL;DR: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive).
Journal ArticleDOI
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.
Antonio Colaprico,Tiago C. Silva,Catharina Olsen,Luciano Garofano,Claudia Cava,Davide Garolini,Thais S. Sabedot,Tathiane M. Malta,Stefano Maria Pagnotta,Isabella Castiglioni,Michele Ceccarelli,Gianluca Bontempi,Houtan Noushmehr +12 more
TL;DR: An R/Bioconductor package called TCGAbiolinks is developed to address bioinformatics challenges of the Cancer Genome Atlas data by using a guided workflow to allow users to query, download and perform integrative analyses of TCGA data.
Related Papers (5)
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
Luciana de Moura Leite,Marcelle Goldner Cesca,Monique Celeste Tavares,Debora Maciel Santana,Erick Figueiredo Saldanha,Paula Tavares Guimarães,Daniella Dias Silva Sá,M.F. Simões,Rafael Lima Viana,F. Rocha,Simone Klog Loose,Sinara Figueiredo Silva,Rafaela Pirolli,Camilla Albina Zanco Fogassa,Bruna Raphaeli Silva Mattos,Fernando Augusto Batista Campos,Solange Moraes Sanches,Vladmir Cláudio Cordeiro de Lima,Noam Pondé +18 more